๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Irinotecan Hydrochloride

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our China, UK, USA and India registers that name Irinotecan Hydrochloride as an intervention. Synced 24 Sep 2026
6Trials tracked
6Recruiting now
4Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Irinotecan Hydrochloride is named as a drug or biological intervention in 6 clinical trials in our China, UK, USA and India trial registers, 6 of which are recruiting. Lead sponsors include Sichuan Baili Pharmaceutical Co., Ltd. (3), Janssen Research & Development, LLC (1) and Daiichi Sankyo (1). Registered phase: Phase 3. Conditions studied include Biliary Tract Cancer; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma.

01

Clinical trials of Irinotecan Hydrochloride

6 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06644781 A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) (ClinicalTrials.gov ↗)
Esophageal Squamous Cell Carcinoma
Phase 3 Recruiting Daiichi Sankyo UK, USA, China
NCT06662786 A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Phase 3 Recruiting Janssen Research & Development, LLC UK, USA, India, China
NCT07463573 QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗)
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 3 Recruiting Qilu Pharmaceutical Co., Ltd. China
NCT07518147 A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment (ClinicalTrials.gov ↗)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. China
NCT07582315 A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) (ClinicalTrials.gov ↗)
Biliary Tract Cancer
Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. China
NCT07606599 A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure (ClinicalTrials.gov ↗)
Biliary Tract Cancer
Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

6 conditions
Condition (as registered)Trials
Biliary Tract Cancer2
Colorectal Neoplasms1
Esophageal Squamous Cell Carcinoma1
Esophageal Squamous Cell Carcinoma (ESCC)1
Gastric Cancer1
Gastroesophageal Junction Adenocarcinoma1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Sichuan Baili Pharmaceutical Co., Ltd.3
Janssen Research & Development, LLC1
Daiichi Sankyo1
Qilu Pharmaceutical Co., Ltd.1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Irinotecan Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Irinotecan Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.